Healthcare / BiotechnologyHKSE
$23.04
-1.50 (-6.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-333.4M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-24.8%
↓Gross Margin
89.0%
↑Debt/Equity
0.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+166.3%
FCF CAGR
—
FCF margin
-678.3%
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $49.2M · net income $-395.3M · FCF $-333.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $49.2M | $49.2M | $6.2M | $6.9M |
| Net Income | $-395.3M | $-395.3M | $-364.4M | $-160.4M |
| EBITDA | $-352.2M | $-352.2M | $-327.8M | $-134.3M |
| EPS | -1.36 | -1.36 | -1.12 | -0.49 |
| Gross Margin | 89.0% | 89.0% | 81.5% | 97.8% |
| Operating Margin | -743.1% | -743.1% | -5835.8% | -2410.1% |
| Net Margin | -804.2% | -804.2% | -5916.1% | -2314.5% |
| Balance Sheet | ||||
| Debt/Equity | 0.20 | 0.20 | 0.21 | 0.15 |
| Current Ratio | 4.12 | 4.12 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $-333.4M | $-333.4M | $-338.1M | $-276.6M |
| Returns | ||||
| ROE | -24.8% | -24.8% | -36.6% | -21.4% |
| Valuation | ||||
| P/B | 4.20 | 4.20 | — | — |
| Growth & Yield | ||||
| Revenue Growth | 698.0% | 698.0% | -11.1% | — |
| EPS Growth | -21.7% | -21.7% | -127.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-63.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.12 → -1.36
Residual
-63.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.